Cargando…
Development and validation of an epithelial–mesenchymal transition-related gene signature for predicting prognosis
BACKGROUND: Currently, there are many therapeutic methods for lung adenocarcinoma (LUAD), but the 5-year survival rate is still only 15% at later stages. Epithelial– mesenchymal transition (EMT) has been shown to be closely associated with local dissemination and subsequent metastasis of solid tumor...
Autores principales: | Zhou, De-Hua, Du, Qian-Cheng, Fu, Zheng, Wang, Xin-Yu, Zhou, Ling, Wang, Jian, Hu, Cheng-Kai, Liu, Shun, Li, Jun-Min, Ma, Meng-Li, Yu, Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477694/ https://www.ncbi.nlm.nih.gov/pubmed/36159424 http://dx.doi.org/10.12998/wjcc.v10.i26.9285 |
Ejemplares similares
-
Development of a lipid metabolism-related gene model to predict prognosis in patients with pancreatic cancer
por: Xu, Hong, et al.
Publicado: (2021) -
A novel epithelial–mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma
por: Shi, Yanlong, et al.
Publicado: (2022) -
Epithelial-mesenchymal transition-related gene signature for prognosis of lung squamous cell carcinoma
por: Yu, Hongmin, et al.
Publicado: (2023) -
Discovery and Validation of an Epithelial-Mesenchymal Transition-Based Signature in Gastric Cancer by Genomics and Prognosis Analysis
por: Xu, Huiyong, et al.
Publicado: (2021) -
Comprehensive Characterization of Immune Landscape Based on Epithelial-Mesenchymal Transition Signature in OSCC: Implication for Prognosis and Immunotherapy
por: Zhang, Si-yuan, et al.
Publicado: (2021)